BioXcel Therapeutics (BTAI) Accounts Payables (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Accounts Payables of $16.2 million for Q1 2026, up 5.16% year-over-year from $15.4 million in Q1 2025, and up 10.52% quarter-over-quarter from $14.7 million in Q4 2025.
BioXcel Therapeutics (BTAI) Accounts Payables (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Accounts Payables history runs 10 years deep, the most recent figure standing at $16.2 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 5.16% year-over-year to $16.2 million; the TTM figure through Mar 2026 stood at $16.2 million (up 5.16% YoY), while the FY2025 annual figure was $14.7 million, down 8.06% from the prior year.
- Accounts Payables for Q1 2026 stood at $16.2 million, up from $14.7 million in the prior quarter.
- The five-year high for Accounts Payables was $17.2 million in Q1 2024, with the low at $5.1 million in Q1 2022.
- The 5-year median for Accounts Payables is $13.7 million (2023), against an average of $12.4 million.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables jumped 141.13% in 2022, then slipped 10.28% in 2025.
- BioXcel Therapeutics' Accounts Payables stood at $10.2 million in 2022, then soared by 33.5% to $13.7 million in 2023, then increased by 17.11% to $16.0 million in 2024, then slipped by 8.06% to $14.7 million in 2025, then gained by 10.52% to $16.2 million in 2026.
- Business Quant data shows BTAI's Accounts Payables at $16.2 million in Q1 2026, $14.7 million in Q4 2025, and $16.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -5.09 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 2.72 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 452.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 2.80 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 497.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.73 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 808.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 427.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 356.00 Mn |
| 10 | BioXcel Therapeutics | 24.29 Mn | 24.29 Mn | 160,000.00 | 18.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.78 Mn |
| Mar 31, 2026 | 16.25 Mn |
| Dec 31, 2025 | 14.70 Mn |
| Sep 30, 2025 | 16.28 Mn |
| Jun 30, 2025 | 16.69 Mn |
| Mar 31, 2025 | 15.45 Mn |
| Dec 31, 2024 | 15.99 Mn |
| Sep 30, 2024 | 14.89 Mn |
| Jun 30, 2024 | 13.26 Mn |
| Mar 31, 2024 | 17.22 Mn |
| Dec 31, 2023 | 13.65 Mn |
| Sep 30, 2023 | 10.67 Mn |
| Jun 30, 2023 | 11.20 Mn |
| Mar 31, 2023 | 7.74 Mn |
| Dec 31, 2022 | 10.23 Mn |
| Sep 30, 2022 | 5.87 Mn |
| Jun 30, 2022 | 6.02 Mn |
| Mar 31, 2022 | 5.07 Mn |
| Dec 31, 2021 | 4.68 Mn |
| Sep 30, 2021 | 3.44 Mn |